CLAIMS

1. Use of a mesenchymal stem cell exosome in the preparation of a medicament for promoting, restoring or enhancing immune homeostasis in an individual suffering from epidermolysis bullosa (EB).

2. Use according to Claim 1, in which the homeostasis comprises maintenance of an immune response.

3. Use according to Claim 1 or 2, in which a therapeutically effective amount of exosome is to be administered to the individual.

4. Use according to Claim 1, 2 or 3, in which the disease comprises epidermolysis bullosa simplex, junctional epidermolysis bullosa, dystrophic epidermolysis bullosa, lethal acantholytic epidermolysis bullosa or epidermolysis bullosa acquisita.

5. Use according to any preceding claim, in which the exosome comprises at least one biological property of a mesenchymal stem cell such as a biological activity of a mesenchymal stem cell conditioned medium (MSC-CM).

6. Use according to Claim 5, in which the biological activity comprisescardioprotection.

7. Use according to any preceding claim, in which the exosome is capable of reducing infarct size for example as assayed in a mouse or pig model of myocardial ischemia and reperfusion injury, or which is capable of reducing oxidative stress for example as assayed in an in vitro assay of hydrogen peroxide (H_2O_2)-induced cell death.

8. Use according to any preceding claim, in which the exosome has a size of between 50 nm and 100 nm as determined by electron microscopy

9. Use of a mesenchymal stem cell exosome in the preparation of a medicament for the treatment or prevention of a disease characterised by an alteration of immune homeostasis, in which the disease comprises epidermolysis bullosa (EB).

10. Use of a mesenchymal stem cell exosome in the preparation of a medicament for promoting, restoring or enhancing immune homeostasis in an individual suffering from or epidermolysis bullosa (EB).